Connecting to LinkedIn...

Pfizer ends Covid-19 trial with 95% efficacy

Posted on 16 days ago by Laurentina Kennedy

W1siziisijiwmjavmtevmtgvmtivmtevmjevota2l2lubm92yxrpb24tcmqgkdawmikuanbnil0swyjwiiwidgh1bwiilcizmdb4mjiwxhuwmdnlil1d















Pfizer ends Covid-19 trial with 95% efficacy

Vaccine was developed with German partner BioNTech
Vaccine was developed with German partner BioNTech

Pfizer Inc said that final results from the late-stage trial of its Covid-19 vaccine show it was 95% effective, adding it had the required two-months of safety data and would apply for emergency US authorisation within days.

The drugmaker said efficacy of the vaccine developed with German partner BioNTech was consistent across age and ethnicity demographics, and that there were no major side effects, a sign that the immunisation could be employed broadly around the world.

Efficacy in adults over 65 years, who are at particular risk from the virus, was over 94%.

The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90% effective.

Moderna Inc on Monday released preliminary data for its vaccine, showing similar effectiveness.

The better-than-expected data from the two vaccines, both developed with new technology known as messenger RNA (mRNA), have raised hopes for an end to a resurgent pandemic that has killed more than 1.3 million people globally and wreaked havoc upon economies and daily life.